Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …

PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials. gov identifier: NCT01405079), a
randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved …

Purpose Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …

Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …

Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …

Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib …

9005 Background: ADJUVANT-CTONG1104, a randomized phase 3 trial showed adjuvant
gefitinib treatment significantly improved disease-free survival (DFS) vs standard doublet …